NO2017024I1 - Elosulfase alfa eller et farmasøytisk akseptabelt salt derav - Google Patents

Elosulfase alfa eller et farmasøytisk akseptabelt salt derav

Info

Publication number
NO2017024I1
NO2017024I1 NO2017024C NO2017024C NO2017024I1 NO 2017024 I1 NO2017024 I1 NO 2017024I1 NO 2017024 C NO2017024 C NO 2017024C NO 2017024 C NO2017024 C NO 2017024C NO 2017024 I1 NO2017024 I1 NO 2017024I1
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
acceptable salt
elosulfase alfa
elosulfase
alfa
Prior art date
Application number
NO2017024C
Other languages
English (en)
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451345&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017024(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of NO2017024I1 publication Critical patent/NO2017024I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001Arylsulfatase (3.1.6.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06014N-Acetylglucosamine-6-sulfatase (3.1.6.14)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/924Hydrolases (3) acting on glycosyl compounds (3.2)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
NO2017024C 2008-01-18 2017-05-30 Elosulfase alfa eller et farmasøytisk akseptabelt salt derav NO2017024I1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2217908P 2008-01-18 2008-01-18
US9937308P 2008-09-23 2008-09-23
US11024608P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
NO2017024I1 true NO2017024I1 (no) 2017-05-30

Family

ID=40451345

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2017024C NO2017024I1 (no) 2008-01-18 2017-05-30 Elosulfase alfa eller et farmasøytisk akseptabelt salt derav

Country Status (28)

Country Link
US (7) US8128925B2 (no)
EP (2) EP2245145B1 (no)
JP (1) JP5687069B2 (no)
KR (1) KR101744142B1 (no)
CN (2) CN102027110A (no)
AR (1) AR070198A1 (no)
AU (1) AU2009205978B2 (no)
BR (1) BRPI0906948B1 (no)
CA (2) CA2711590C (no)
CL (1) CL2009000091A1 (no)
CY (2) CY1118984T1 (no)
DK (1) DK2245145T3 (no)
HK (1) HK1244505A1 (no)
HR (1) HRP20170366T1 (no)
HU (2) HUE032074T2 (no)
IL (1) IL206975A (no)
LT (2) LT2245145T (no)
MX (1) MX2010007846A (no)
NL (1) NL300874I2 (no)
NO (1) NO2017024I1 (no)
PE (2) PE20140841A1 (no)
PL (1) PL2245145T3 (no)
PT (1) PT2245145T (no)
RU (1) RU2510820C2 (no)
SI (1) SI2245145T1 (no)
TW (1) TWI395816B (no)
WO (1) WO2009091994A2 (no)
ZA (1) ZA201004674B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5967861B2 (ja) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド 分子のグリコシル化
WO2009091994A2 (en) * 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2483399B1 (en) 2009-09-29 2019-03-27 Universiteit Gent Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
JP2013511272A (ja) 2009-11-19 2013-04-04 オキシレイン ユーケー リミテッド 哺乳類様複合n−グリカンを生成する酵母株
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
SG189108A1 (en) 2010-09-29 2013-05-31 Oxyrane Uk Ltd Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
CA2812872C (en) 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
KR101535791B1 (ko) * 2010-11-12 2015-07-10 주식회사 녹십자 개량형 이듀로네이트-2-설파타제 및 이의 용도
CA2822559C (en) * 2010-12-22 2021-11-30 Fondazione Telethon Therapeutic strategies to treat cns pathology in mucopolysaccharidoses
TW201307563A (zh) 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素-n-硫酸酯酶之方法
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
BR112014022624A2 (pt) 2012-03-15 2017-07-11 Oxyrane Uk Ltd métodos e materiais para tratamento de doença de pompe
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014075688A1 (en) * 2012-11-13 2014-05-22 Ace Biosciences A/S PURIFICATION OF RECOMBINANT HUMAN GALACTOCEREBROSIDE β-GALACTOSIDASE (rhGALC)
US20190040368A1 (en) * 2013-03-05 2019-02-07 Oxyrane Uk Limited Production of catalytically active type i sulfatase
EP3108258B1 (en) 2014-02-18 2019-12-04 Shire Human Genetic Therapies, Inc. Substrate clearance assays for lysosomal enzymes
EP2970413B1 (en) * 2014-04-01 2018-07-04 Swedish Orphan Biovitrum AB (Publ) Modified sulfamidase and production thereof
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
MX2018005258A (es) 2015-11-06 2019-09-04 Biomarin Pharm Inc Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.
RU2673038C2 (ru) * 2016-01-18 2018-11-21 ООО "Международный Биотехнологический Центр "Генериум" Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа
JP6430980B2 (ja) * 2016-03-09 2018-11-28 フォンダッツィオーネ・テレソン ムコ多糖症におけるcns病変を処置するための治療戦略
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
PE20210347A1 (es) 2017-10-02 2021-02-25 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas
EP3963073A4 (en) * 2019-04-29 2023-01-25 The University of North Carolina at Chapel Hill OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTE AND THEIR USE
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
WO2023022629A1 (ru) * 2021-08-18 2023-02-23 Акционерное общество "ГЕНЕРИУМ" Направленная доставка терапевтических ферментов

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6972124B2 (en) 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
WO2002074969A2 (en) 2001-01-26 2002-09-26 University Of Lausanne Matrix attachment regions and methods for use thereof
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
AUPS293002A0 (en) * 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
MX345056B (es) * 2003-02-11 2017-01-16 Transkaryotic Therapies Inc Diagnóstico y tratamiento de deficiencia de sulfatasa múltiple y otras deficiencias de sulfatasa.
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
BRPI0507440A (pt) * 2004-02-06 2007-07-10 Biomarin Pharm Inc fabricação de enzimas lisossomais altamente fosforiladas e uso das mesmas
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
CA2607133A1 (en) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
WO2009034159A1 (en) 2007-09-12 2009-03-19 Vivendy Therapeutics Ltd: Short polypeptide mediated conformational changes promoting enhancement of enzymatic activity
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2009091994A2 (en) 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos

Also Published As

Publication number Publication date
AU2009205978A1 (en) 2009-07-23
US8420368B2 (en) 2013-04-16
SI2245145T1 (sl) 2017-05-31
CL2009000091A1 (es) 2009-03-27
PE20091319A1 (es) 2009-09-23
US9873867B2 (en) 2018-01-23
CY1118984T1 (el) 2017-11-14
HK1244505A1 (zh) 2018-08-10
RU2010134412A (ru) 2012-02-27
ZA201004674B (en) 2011-09-28
CY2017018I2 (el) 2017-11-14
HUE032074T2 (en) 2017-08-28
WO2009091994A2 (en) 2009-07-23
EP2245145B1 (en) 2016-12-14
US20130236921A1 (en) 2013-09-12
MX2010007846A (es) 2010-10-05
US10563183B2 (en) 2020-02-18
LT2245145T (lt) 2017-04-10
DK2245145T3 (en) 2017-03-20
JP5687069B2 (ja) 2015-03-18
US20210189357A1 (en) 2021-06-24
LTC2245145I2 (lt) 2019-04-25
AU2009205978B2 (en) 2014-04-10
KR20100108438A (ko) 2010-10-06
BRPI0906948B1 (pt) 2023-05-16
PE20140841A1 (es) 2014-08-03
US8128925B2 (en) 2012-03-06
WO2009091994A3 (en) 2009-10-29
CA2711590A1 (en) 2009-07-23
BRPI0906948A2 (pt) 2015-07-14
EP2245145A2 (en) 2010-11-03
US20180208913A1 (en) 2018-07-26
US10934534B2 (en) 2021-03-02
TWI395816B (zh) 2013-05-11
CY2017018I1 (el) 2017-11-14
LTPA2017016I1 (lt) 2017-06-12
CA3112632A1 (en) 2009-07-23
US20120208221A1 (en) 2012-08-16
EP3219795A1 (en) 2017-09-20
TW200934869A (en) 2009-08-16
PT2245145T (pt) 2017-03-14
JP2011509674A (ja) 2011-03-31
NL300874I2 (nl) 2018-04-12
IL206975A (en) 2013-06-27
US20200181590A1 (en) 2020-06-11
US20090186011A1 (en) 2009-07-23
RU2510820C2 (ru) 2014-04-10
CN105274072A (zh) 2016-01-27
PL2245145T3 (pl) 2017-07-31
CN102027110A (zh) 2011-04-20
CA2711590C (en) 2021-03-23
IL206975A0 (en) 2010-12-30
HUS1700022I1 (hu) 2017-06-28
EP3219795B1 (en) 2024-03-13
KR101744142B1 (ko) 2017-06-07
HRP20170366T1 (hr) 2017-05-05
AR070198A1 (es) 2010-03-17
US9200264B2 (en) 2015-12-01
US20160201039A1 (en) 2016-07-14
WO2009091994A9 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2017024I1 (no) Elosulfase alfa eller et farmasøytisk akseptabelt salt derav
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2017059I2 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2020001I1 (no) Gilteritinib eller et salt derav
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NO2021013I1 (no) filgotinib or a salt thereof
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2017057I1 (no) pibrentasvir eller et farmasøytisk akseptabelt salt derav
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NO2020047I1 (no) Remdesivir eller et farmasøytisk akseptabelt salt eller ester derav
NO2024006I1 (no) Piflufolastat (18F) or a pharmaceutically acceptable salt thereof
FIC20230039I1 (fi) Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2016016I1 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
NO2015014I1 (no) Paritaprevir, eller et farmasøytisk akseptabelt salt eller ester derav
NO2022056I1 (no) avalglucosidase alfa
NO2015012I1 (no) Ombitasvir, eller et farmasøytisk akseptabelt salt derav
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2017021I1 (no) Etelkalsetid, eller et salt derav, inkludert etelkalsetidhydroklorid
BRPI0922322A2 (pt) endoscópio com uma porção curvada
IT1393131B1 (it) Controvento a ingobbamento limitato
NO2023002I1 (no) Lasmiditan or a pharmaceutically acceptable salt thereof